What is the CORONA Remedies Ltd share price today?

The share price of NSE:CORONA-EQ on 07 Sep 2026 (as of 10:59:05 IST) is ₹2096.90.

What is the NSE:CORONA-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:CORONA-EQ 52 week high low range shows a high of ₹2270.10 and a low of ₹1336.60.

What is the CORONA Remedies Ltd market cap?

As on 07 Sep 2026, CORONA Remedies Ltd market cap is ₹12843.00 Cr.

What is the shareholding pattern of CORONA Remedies Ltd Stock?

The shareholding pattern of CORONA Remedies Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 69% Foreign Institutional Investors (FII): 3.63% Domestic Institutional Investors (DII): 0.40% Mutual Funds: 12.50% Retail & Others: 14.47% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of CORONA Remedies Ltd?

The Price-to-Earnings (PE) ratio of CORONA Remedies Ltd is 64.53, and the Price-to-Book (PB) ratio is 12.74, as on 07 Sep 2026.

CORONA Remedies Share Price

2111.00+0.00 (-2.42%)

+46.76% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-2.42%

1 Week

-4.12%

1 Month

+0.38%

3 Month

+11.50%

6 Month

+33.49%

YTD

+52.43%

1 Year

5 Year

10 Year

Max

+43.61%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

2101.00

2020.20

1890.00

1372.30

1336.60

High

2163.40

2247.90

2292.40

About

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

CORONANSE

LTP

1W Low

1W High

Market cap (₹)

1849.9+12.6 (0.69%)

1832.20

1891.50

4,47,476Cr

9602+227 (2.42%)

9312.50

9740

2,54,764Cr

4928.5+88.5 (1.83%)

4848.50

5010

1,89,423Cr

1180.3+20.3 (1.75%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2026.2+72.2 (3.69%)

1963.80

2055.30

1,09,943Cr

2500+199.3 (8.66%)

2303

2504.30

1,01,712Cr

1200.4+15.4 (1.30%)

1185

1222

1,01,005Cr

1716-18 (-1.04%)

1689.30

1740

99,253Cr

2100.7+17.7 (0.85%)

2080

2135

96,031Cr

2118-83.8 (-3.81%)

2101

2247.90

13,237Cr

CORONA Remedies Share Price

2111.00+0.00 (-2.42%)

+46.76% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years17%

Last year17%

Compounded Profit Growth

10 years-

5 years-

3 years30%

Last year24%

Stock Price CAGR

10 years-

5 years-

3 years-

1 year-

Return on Equity

10 years24%

5 years24%

3 years25%

Last year27%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	17%	17%
-	-	30%	24%
-	-	-	-
24%	24%	25%	27%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

CORONA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.9	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,602	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,928.5	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180.3	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,500	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,716	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,100.7	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
2,118	₹13237 Cr	66.51	9.83	39.44	₹185 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023
—	—	—	—
₹61 Cr	₹61 Cr	₹61 Cr	₹61 Cr
₹686 Cr	₹545 Cr	₹419 Cr	₹347 Cr
₹686 Cr	₹545 Cr	₹419 Cr	₹347 Cr
₹747 Cr	₹606 Cr	₹480 Cr	₹409 Cr
₹0	₹16 Cr	₹67 Cr	₹0
₹12 Cr	₹8 Cr	₹4 Cr	-₹4 Cr
₹19 Cr	₹21 Cr	₹23 Cr	₹24 Cr
₹66 Cr	₹39 Cr	₹32 Cr	₹25 Cr
₹97 Cr	₹84 Cr	₹126 Cr	₹45 Cr
—	—	—	—
₹147 Cr	₹144 Cr	₹114 Cr	₹94 Cr
₹46 Cr	₹52 Cr	₹50 Cr	₹18 Cr
₹127 Cr	₹11 Cr	₹31 Cr	₹2 Cr
₹135 Cr	₹121 Cr	₹73 Cr	₹94 Cr
₹455 Cr	₹327 Cr	₹269 Cr	₹209 Cr
₹1299 Cr	₹1017 Cr	₹875 Cr	₹663 Cr
₹1 Cr	₹0	₹0	₹0
₹143 Cr	₹63 Cr	₹134 Cr	₹2 Cr
—	—	—	—
₹724 Cr	₹503 Cr	₹483 Cr	₹256 Cr
₹170 Cr	₹133 Cr	₹99 Cr	₹72 Cr
₹554 Cr	₹370 Cr	₹384 Cr	₹185 Cr
₹143 Cr	₹186 Cr	₹121 Cr	₹65 Cr
₹26 Cr	₹26 Cr	₹26 Cr	₹26 Cr
₹26 Cr	₹26 Cr	₹26 Cr	₹26 Cr
₹5 Cr	₹9 Cr	₹9 Cr	₹10 Cr
₹129 Cr	₹10 L	₹2 Cr	₹15 Cr
₹857 Cr	₹591 Cr	₹541 Cr	₹299 Cr
—	—	—	—
₹0	₹0	₹0	₹6 Cr
₹125 Cr	₹129 Cr	₹98 Cr	₹105 Cr
₹146 Cr	₹118 Cr	₹100 Cr	₹87 Cr
₹44 Cr	₹69 Cr	₹70 Cr	₹77 Cr
₹2 Cr	₹7 Cr	₹4 Cr	₹3 Cr
₹125 Cr	₹102 Cr	₹63 Cr	₹85 Cr
₹442 Cr	₹426 Cr	₹335 Cr	₹363 Cr
-₹13 Cr	₹99 Cr	₹66 Cr	₹154 Cr
₹1299 Cr	₹1017 Cr	₹875 Cr	₹663 Cr
₹122	₹99	₹79	₹67
₹122	₹99	₹79	₹67

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023
₹240 Cr	₹199 Cr	₹118 Cr	₹111 Cr
₹44 Cr	₹52 Cr	₹47 Cr	₹23 Cr
-₹6 Cr	-₹17 Cr	₹9 Cr	-₹5 Cr
₹279 Cr	₹234 Cr	₹175 Cr	₹129 Cr
₹229 Cr	₹190 Cr	₹157 Cr	₹103 Cr
-₹256 Cr	-₹84 Cr	-₹267 Cr	-₹50 Cr
₹25 Cr	-₹107 Cr	₹99 Cr	-₹45 Cr
-₹1 Cr	₹6 L	-₹11 Cr	₹8 Cr
₹3 Cr	₹3 Cr	₹14 Cr	₹7 Cr
₹0	₹0	₹20,000	-₹4 L
₹2 Cr	₹3 Cr	₹3 Cr	₹14 Cr

Fundamental Ratios

Consolidated

Standalone

CORONA Remedies Share Price

2111.00+0.00 (-2.42%)

+46.76% past 1 Year

Shareholding summary

Promoters

69%

FII

3.63%

DII

0.4%

12.5%

Others

14.47%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025
69.00%	69.00%	69.00%
3.63%	2.25%	1.84%
0.40%	0.67%	0.39%
12.50%	6.35%	6.38%
14.47%	21.73%	22.39%

Bulk & block deals

Name

Sbi Mutual Fund

Amundi Funds Asia Equity Concentrated

Sepia Investments Limited

Hdfc Mutual Fund

Aditya Birla Sun Life Mutual Fund

Aberdeen Asian Smaller Companies Investment Trust Plc

Sepia Investments Limited

Hdfc Mutual Fund

Aditya Birla Sun Life Mutual Fund

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
10 Sep 2026	Purchase	176.30 Cr	₹2,050	8.60 L	Bulk	1.406146	BSE
10 Sep 2026	Purchase	139.40 Cr	₹2,050	6.80 L	Bulk	1.111836	BSE
10 Sep 2026	Purchase	63.96 Cr	₹2,050	3.12 L	Bulk	0.510137	BSE
10 Sep 2026	Sell	509.60 Cr	₹2,050.32	24.85 L	Bulk	4.063885	BSE
17 Jun 2026	Purchase	403.67 Cr	₹1,730	23.33 L	Bulk	3.815123	NSE
17 Jun 2026	Purchase	79.93 Cr	₹1,730	4.62 L	Bulk	0.755452	NSE
17 Jun 2026	Purchase	78 Cr	₹1,730	4.51 L	Bulk	0.737193	NSE
17 Jun 2026	Sell	748.91 Cr	₹1,730	43.29 L	Bulk	7.078051	NSE
17 Jun 2026	Purchase	423.85 Cr	₹1,730	24.50 L	Block	4.00588	NSE
17 Jun 2026	Purchase	84.77 Cr	₹1,730	4.90 L	Block	0.801176	NSE

Insider trading & SAST

Client name

Kirtisinh Manoharsinh Parmar

Apurvsinh Kirtisinh Parmar

Kirtisinh Manoharsinh Parmar

Ranjanben Kirtisinh Parmar

Apurvsinh Kirtisinh Parmar

Reported on	Client category	Action	%Stake traded	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
19 Aug 2026	Immediate Relative	Acquisition	0.00001	12.49 K	₹2,082.33	6	05 Aug 2026 - 06 Aug 2026	Market Purchase	197	Insider Trading	—	Equity
19 Aug 2026	Designated Person	Acquisition	0.000082	1.05 L	₹2,104.84	50	05 Aug 2026 - 06 Aug 2026	Market Purchase	100	Insider Trading	—	Equity
19 Aug 2026	Designated Person	Acquisition	0.000082	1.07 L	₹2,135.02	50	05 Aug 2026 - 06 Aug 2026	Market Purchase	50	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.000082	1.05 L	₹2,092.40	50	05 Aug 2026 - 06 Aug 2026	Market Purchase	296	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.000002	2.08 K	₹2,082	1	05 Aug 2026 - 06 Aug 2026	Market Purchase	246	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.000003	4.14 K	₹2,072.50	2	05 Aug 2026 - 06 Aug 2026	Market Purchase	298	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.000078	99.47 K	₹2,072.33	48	05 Aug 2026 - 06 Aug 2026	Market Purchase	245	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.00007	89.54 K	₹2,082.37	43	05 Aug 2026 - 06 Aug 2026	Market Purchase	341	Insider Trading	—	Equity
19 Aug 2026	Immediate Relative	Acquisition	0.000123	1.57 L	₹2,089.73	75	05 Aug 2026 - 06 Aug 2026	Market Purchase	165	Insider Trading	—	Equity
19 Aug 2026	Designated Person	Acquisition	0.000082	1.03 L	₹2,064.54	50	05 Aug 2026 - 06 Aug 2026	Market Purchase	150	Insider Trading	—	Equity

CORONA Remedies Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

CORONA Remedies Share Price

CORONA Remedies Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

CORONA Remedies Share Price

CORONA Remedies Share Price

Oscillators

Moving averages

CORONA Remedies Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

CORONA Remedies Share Price

Corporate Actions

Company details

CORONA Remedies Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

CORONA Remedies Share Price

News

Corona Remedies to host analyst and investor meet on August 26, 2026

Corona Remedies posts higher Q1 EBITDA and improved margin

Corona Remedies reports strong year-on-year revenue growth in Q1 results

Corona Remedies reports higher first quarter net profit on revenue growth

Corona Remedies starts EU-GMP certified women’s hormone facility in Ahmedabad

Corona Remedies informs about investor meetings

CORONA Remedies rises on getting EU-GMP certification for Hormone manufacturing facility

CORONA Remedies gets EU-GMP certification for Hormone manufacturing facility

CORONA Remedies - Quaterly Results

Corona Remedies Announces Final Dividend of Rs 10 Per Share

Corona Remedies Reports Q4 EBITDA Growth to Rs 61 Crores, Margin Slightly Declines YoY

Corona Remedies Q4 Net Profit Rises 44% YoY to Rs 45.10 Crores, Revenue Up 20% to Rs 353 Crores

CORONA Remedies reports Profit after tax of 45.05 Crores, in the March 2026 quarter

Corona Remedies Reports OCF to EBITDA Ratio of 87%, Enabling Further Acquisitions.

Corona Remedies Reports Rs 112 Cr Cash as of Dec 31, Targets 20-25% CAGR for Wpladone Over 3 Years.

CORONA Remedies acquires ‘Wokadine’ from Dr. Reddy’s Laboratories

Corona Remedies informs about analyst meet

CORONA Remedies - Quaterly Results

Corona Remedies Reports Strong Q3 EBITDA Growth with Margin Expansion YoY.

Corona Remedies Q3FY26 Net Profit at Rs 41.30 Crores Down 7.8% YoY, Revenue Up 14.5% to Rs 340 Crores.

CORONA Remedies Ltd Share Price Today

CORONA Remedies Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator